The fight against COVID19
23.82k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
14 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 152.3871 | -1.01 | -0.66% | 11:09 am GMT-4 | 1.75M | 7.42M | 366.75B |
| ABBV | AbbVie Inc. | 165.875 | -0.54 | -0.33% | 11:08 am GMT-4 | 558.70k | 5.62M | 292.91B |
| PFE | Pfizer Inc. | 28.625 | -0.01 | -0.05% | 11:09 am GMT-4 | 8.96M | 42.61M | 162.21B |
| SNY | Sanofi | 48.455 | -0.21 | -0.44% | 11:07 am GMT-4 | 259.63k | 1.98M | 122.26B |
| REGN | Regeneron Pharmaceuticals, Inc. | 982.45 | +0.16 | +0.02% | 11:07 am GMT-4 | 66.81k | 456.01k | 108.25B |
| GSK | GSK plc | 45.0805 | +0.10 | +0.22% | 11:09 am GMT-4 | 376.34k | 3.14M | 94.01B |
| GILD | Gilead Sciences, Inc. | 67.6601 | -0.06 | -0.09% | 11:09 am GMT-4 | 545.48k | 6.95M | 84.29B |
| MRNA | Moderna, Inc. | 138.6408 | +5.74 | +4.32% | 11:09 am GMT-4 | 1.33M | 3.83M | 53.13B |
| TAK | Takeda Pharmaceutical Company Limited | 13.3 | +0.08 | +0.61% | 11:06 am GMT-4 | 138.63k | 1.65M | 41.95B |
| BNTX | BioNTech SE | 90.89 | +0.28 | +0.31% | 11:08 am GMT-4 | 69.76k | 593.47k | 21.90B |
| NVAX | Novavax, Inc. | 14.1793 | +1.17 | +8.99% | 11:09 am GMT-4 | 4.17M | 12.93M | 2.09B |
| VIR | Vir Biotechnology, Inc. | 9.66 | -0.07 | -0.72% | 11:09 am GMT-4 | 188.93k | 982.48k | 1.31B |
| INO | Inovio Pharmaceuticals, Inc. | 11.37 | -0.63 | -5.23% | 11:09 am GMT-4 | 97.64k | 441.90k | 294.60M |
Motley Fool1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
Revenue growth during what should be a disastrous patent cliff is encouraging.
ReutersShah Capital ends campaign against Novavax board after Sanofi deal
Under a deal signed on May 10, the French drugmaker will take a 4.9% stake in Novavax for $70 million at a lofty valuation. Novavax, which struggled to get its protein-based vaccine to the market in a timely manner, also removed a warning notice from February last year that raised doubts about it being in business after the deal. The fund, which owns an about 7.8% stake in Novavax, reiterated that the Sanofi agreement was a "long-awaited step in the right direction".
GuruFocus.comJohnson & Johnson's Dividend Analysis
Johnson & Johnson (NYSE:JNJ) recently announced a dividend of $1.24 per share, payable on 2024-06-04, with the ex-dividend date set for 2024-05-20. Using the data from GuruFocus, let's delve into Johnson & Johnson's dividend performance and assess its sustainability. What Does Johnson & Johnson Do?
